BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003-1016. [PMID: 16984494 DOI: 10.1111/j.1365-2036.2006.03081.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Hoda K, Nguyen MH. Chronic hepatitis B virus infection in patients with “Normal” ALT levels. Current Hepatitis Reports 2007;6:24-9. [DOI: 10.1007/bf02942175] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-575. [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
3 Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, Huang HH, Chen FY, Zheng MH. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7:30642-30658. [PMID: 27121321 DOI: 10.18632/oncotarget.8907] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
4 Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohnʼs disease: . Inflammatory Bowel Diseases 2007;13:1453-4. [DOI: 10.1002/ibd.20216] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
5 Tseng CM, Chen TB, Hsu YC, Chang CY, Lin JT, Mo LR. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol 2016;12:421-9. [PMID: 27435683 DOI: 10.1111/ajco.12520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opinion on Biological Therapy 2014;14:1019-31. [DOI: 10.1517/14712598.2014.912273] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lin CL, Chien RN, Yeh C, Hsu CW, Chang ML, Chen YC, Yeh CT. Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. Scand J Gastroenterol. 2014;49:1456-1464. [PMID: 25283499 DOI: 10.3109/00365521.2014.962604] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
8 Charbel H, Lewis JH. Hepatitis B Reactivation in the Setting of Chemotherapy and Immunosuppression. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 307-36. [DOI: 10.1007/978-1-59745-565-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Tang W, Chen L, Zheng R, Pan L, Gao J, Ye X, Zhang X, Zheng W. Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis. PLoS One 2015;10:e0128673. [PMID: 26057738 DOI: 10.1371/journal.pone.0128673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, Cameron W. The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. Journal of Clinical Virology 2008;41:243-54. [DOI: 10.1016/j.jcv.2007.11.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
11 Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat. 2008;15:89-102. [PMID: 18184191 DOI: 10.1111/j.1365-2893.2007.00902.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 0.7] [Reference Citation Analysis]
12 Yang F, Zhu HL, He C, Li JJ, Xiang B, Cui X, Huang J, Ji J, Ma HB, Liu T. Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. Indian J Hematol Blood Transfus 2014;30:97-104. [PMID: 24839363 DOI: 10.1007/s12288-012-0195-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Pol S. Management of HBV in immunocompromised patients. Liver Int. 2013;33 Suppl 1:182-187. [PMID: 23286863 DOI: 10.1111/liv.12055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
14 Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis. 2009;1:e2009025. [PMID: 21415959 DOI: 10.4084/mjhid.2009.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
15 Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519-528. [PMID: 18378948 DOI: 10.7326/0003-4819-148-7-200804010-00008] [Cited by in Crossref: 321] [Cited by in F6Publishing: 295] [Article Influence: 24.7] [Reference Citation Analysis]
16 Castillo RD, De la Pena W, Marzan KA. Diagnosis and management of infectious complications of childhood rheumatic diseases. Curr Rheumatol Rep 2013;15:322. [PMID: 23443616 DOI: 10.1007/s11926-013-0322-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Pol S, Vallet-pichard A. Hépatite chronique B : situations rares : dialyse, transplantation rénale et traitements pré-emptifs en situation d’immunosuppression. Gastroentérologie Clinique et Biologique 2008;32:S34-41. [DOI: 10.1016/s0399-8320(08)73263-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015;114:164-173. [PMID: 25678179 DOI: 10.1016/j.jfma.2012.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
20 Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46:1034-1040. [PMID: 17654490 DOI: 10.1002/hep.21784] [Cited by in Crossref: 159] [Cited by in F6Publishing: 149] [Article Influence: 11.4] [Reference Citation Analysis]
21 Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31. [PMID: 24533834 DOI: 10.1186/1471-230X-14-31] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
22 Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol. 2007;39:48-50. [PMID: 17368969 DOI: 10.1016/j.jcv.2007.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
23 Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397-408. [PMID: 17382608 DOI: 10.1016/j.dld.2006.12.017] [Cited by in Crossref: 152] [Cited by in F6Publishing: 154] [Article Influence: 10.9] [Reference Citation Analysis]
24 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
25 Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016;164:30-40. [PMID: 26595058 DOI: 10.7326/M15-1121] [Cited by in Crossref: 92] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
26 Parker S, Gil E, Hewitt P, Ward K, Reyal Y, Wilson S, Manson J. Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin. BMC Infect Dis 2014;14:99. [PMID: 24559411 DOI: 10.1186/1471-2334-14-99] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
27 Fujimoto Y, Hashimoto N, Kinoshita M, Miyazaki Y, Tanaka S, Yakushijin T, Takehara T, Kagawa N, Yoshimine T. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol 2012;17:290-3. [PMID: 21809177 DOI: 10.1007/s10147-011-0294-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
28 Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 2013;87:12-27. [PMID: 23313021 DOI: 10.1016/j.critrevonc.2012.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
29 Oliver NT, Nieto YL, Blechacz B, Anderlini P, Ariza-Heredia E, Torres HA. Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation. Bone Marrow Transplant 2017;52:138-40. [PMID: 27427916 DOI: 10.1038/bmt.2016.196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
30 Sun WC, Hsu PI, Yu HC, Lin KH, Tsay FW, Wang HM, Tsai TJ, Chen WC, Lai KH, Cheng JS. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One. 2015;10:e0116978. [PMID: 25658926 DOI: 10.1371/journal.pone.0116978] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
31 Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011;127:705-712. [PMID: 21445574 DOI: 10.1007/s10549-011-1455-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
32 Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:794-810. [PMID: 23319691 DOI: 10.1200/JCO.2012.45.8661] [Cited by in Crossref: 271] [Cited by in F6Publishing: 95] [Article Influence: 33.9] [Reference Citation Analysis]
33 Zheng Y, Zhang S, Tan Grahn HM, Ye C, Gong Z, Zhang Q. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. Hepat Mon. 2013;13:e6496. [PMID: 23805156 DOI: 10.5812/hepatmon.6496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
34 Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int. 2012;32:21-27. [PMID: 22098398 DOI: 10.1111/j.1478-3231.2011.02629.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
35 Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokhar F, Lutchman G, Kleiner DE, Young NS, Childs R, Barrett AJ, Liang TJ, Hoofnagle JH, Heller T. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009;7:1130-7. [PMID: 19577007 DOI: 10.1016/j.cgh.2009.06.027] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
36 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 373] [Article Influence: 29.1] [Reference Citation Analysis]
37 Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104:435-443. [PMID: 30733266 DOI: 10.3324/haematol.2018.210252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
38 Dizdar O, Tapan U, Aksoy S, Harputluoglu H, Kilickap S, Barista I. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol. 2008;80:381-385. [PMID: 18221389 DOI: 10.1111/j.1600-0609.2008.01039.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
39 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer 2011;19:1779-87. [PMID: 20927554 DOI: 10.1007/s00520-010-1019-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
41 Phillips KA, Fadul CE, Schiff D. Neurologic and Medical Management of Brain Tumors. Neurol Clin 2018;36:449-66. [PMID: 30072065 DOI: 10.1016/j.ncl.2018.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
42 Sun WC, Tang PL, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Cheng JS, Tsai WL. Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study. Front Med (Lausanne) 2021;8:657109. [PMID: 34336877 DOI: 10.3389/fmed.2021.657109] [Reference Citation Analysis]
43 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
44 Toka B, Koksal AS, Eminler AT, Tozlu M, Uslan MI, Parlak E. Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation. Dig Dis Sci 2021;66:2417-26. [PMID: 32729014 DOI: 10.1007/s10620-020-06506-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 60.3] [Reference Citation Analysis]
46 Vierling JM. The immunology of hepatitis B. Clin Liver Dis. 2007;11:727-759, vii-viii. [PMID: 17981227 DOI: 10.1016/j.cld.2007.08.001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
47 Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, Carman W. Erratum to ‘The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting’ [J. Clin. Virol. 41 (4) 2008 243–254]. Journal of Clinical Virology 2008;42:104-15. [DOI: 10.1016/j.jcv.2008.03.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
48 Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10:2399-2406. [PMID: 19761353 DOI: 10.1517/14656560903251710] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
49 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Yağci M, Ozkurt ZN, Yeğin ZA, Aki Z, Sucak GT, Haznedar R. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010;15:240-4. [PMID: 20670484 DOI: 10.1179/102453309X12583347114059] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
51 Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999-3008. [PMID: 22933131 DOI: 10.1007/s00520-012-1576-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
52 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 8.3] [Reference Citation Analysis]
54 Ghrénassia E, Mékinian A, Rouaghe S, Ganne N, Fain O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2012;79:100-101. [PMID: 21944979 DOI: 10.1016/j.jbspin.2011.07.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
55 Xu Z, Dai W, Wu YT, Arshad B, Li X, Wu H, Chen HR, Wu KN, Kong LQ. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis. Eur J Cancer Care (Engl) 2018;27:e12799. [PMID: 29265535 DOI: 10.1111/ecc.12799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Cheng J, Pei HH, Sun J, Xie QX, Li JB. Radiation-induced hepatitis B virus reactivation in hepatocellular carcinoma: A case report. Oncol Lett 2015;10:3213-5. [PMID: 26722314 DOI: 10.3892/ol.2015.3724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864-871. [PMID: 20546439 DOI: 10.1111/j.1440-1746.2010.06243.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
58 Lee HJ, Kim DY, Keam B, Lee JH, Han S, Oh D, Yoon JH, Kim T, Kim YJ, Lee KW, Kim J, Jeong S, Lee JS, Kim JH, Im S. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. Breast Cancer 2014;21:387-93. [DOI: 10.1007/s12282-012-0417-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
59 Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011;43 Suppl 1:S40-S48. [PMID: 21195371 DOI: 10.1016/s1590-8658(10)60691-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
60 Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007;19:619-25. [PMID: 17917544 DOI: 10.1097/BOR.0b013e3282f05b63] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
61 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
62 Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ. Hepatitis B reactivation and rituximab in the oncology practice. Oncologist. 2010;15:1113-1121. [PMID: 20930099 DOI: 10.1634/theoncologist.2010-0106] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
63 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
64 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
65 Su YC, Lin PC, Yu HC, Wu CC. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:1111-1119. [PMID: 29845351 DOI: 10.1007/s00228-018-2487-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-S165. [PMID: 19399803 DOI: 10.1002/hep.22945] [Cited by in Crossref: 375] [Cited by in F6Publishing: 327] [Article Influence: 31.3] [Reference Citation Analysis]
67 Post A, Nagendra S. Reactivation of hepatitis B: pathogenesis and clinical implications. Curr Infect Dis Rep 2009;11:113-9. [PMID: 19239801 DOI: 10.1007/s11908-009-0017-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
68 张俊新, 郎佳凤, 刘燕南. 拉米夫定联合乙肝疫苗治疗慢性乙型肝炎39例. 世界华人消化杂志 2009; 17(6): 614-617 [DOI: 10.11569/wcjd.v17.i6.614] [Reference Citation Analysis]
69 Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005. [PMID: 19454492 DOI: 10.3324/haematol.2009.005819] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
70 阮杰, 李海军, 孙殿兴. 乙型肝炎病毒的复制再活化. 世界华人消化杂志 2014; 22(7): 927-932 [DOI: 10.11569/wcjd.v22.i7.927] [Reference Citation Analysis]
71 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 24.2] [Reference Citation Analysis]
72 Chtioui H, Millius C, Lämmle B, Lauterburg BH. Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. British Journal of Haematology 2009;144:136-7. [DOI: 10.1111/j.1365-2141.2008.07432.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
73 Kim IK, Kim BG, Kim W, Kim D, Kim YJ, Yoon JH, Lee HS. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother 2012;56:5511-9. [PMID: 22890764 DOI: 10.1128/AAC.00821-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
74 Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47:844-853. [PMID: 18302293 DOI: 10.1002/hep.22106] [Cited by in Crossref: 224] [Cited by in F6Publishing: 207] [Article Influence: 17.2] [Reference Citation Analysis]
75 Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52. [PMID: 21819330 DOI: 10.1586/eri.11.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]